Highly elevated level of antimüllerian hormone associated with preterm delivery in polycystic ovary syndrome patients who underwent ovulation induction

Pregnancy and ChildbirthReproductive Health

Highly elevated level of antimüllerian hormone associated with preterm delivery in polycystic ovary syndrome patients who underwent ovulation induction

Fertil Steril

Kaing A, Jaswa EA, Diamond MP, Legro RS, Cedars MI, Huddleston HG

doi: 10.1016/j.fertnstert.2020.06.015

Pregnancy and ChildbirthReproductive Health

First-line ovulation induction for polycystic ovary syndrome: an individual participant data meta-analysis

Hum Reprod Update.

Wang R, Li W, Bordewijk EM, Legro RS, Zhang H, Wu X, Gao J, Morin-Papunen L, Homburg R, König TE, Moll E, Kar S, Huang W, Johnson NP, Amer SA, Vegetti W, Palomba S, Falbo A, Özmen Ü, Nazik H, Williams CD, Federica G, Lord J, Sahin Y, Bhattacharya S, Norman RJ, van Wely M, Mol BW, Reproductive Medicine Network+., International Ovulation Induction IPDMA Collaboration.

doi: 10.1093/humupd/dmz029.

Reproductive Health

The regulation and signalling of anti-Müllerian hormone in human granulosa cells: relevance to polycystic ovary syndrome

Hum Reprod.

Dilaver N, Pellatt L, Jameson E, Ogunjimi M, Bano G, Homburg R, D Mason H, Rice S

doi: 10.1093/humrep/dez214.

Reproductive Health

Significance of pro-angiogenic estrogen metabolites in normal follicular development and follicular growth arrest in polycystic ovary syndrome

Hum Reprod.

Henríquez S, Kohen P, Xu X, Villarroel C, Muñoz A, Godoy A, Strauss JF, Devoto L

doi: 10.1093/humrep/deaa098.

Further Publications UrologyFurther Publications Gynecology

A genome-wide association study of polycystic ovary syndrome identified from electronic health records

Am J Obstet Gynecol.

Zhang Y, Ho K, Keaton JM, Hartzel DN, Day F, Justice AE, Josyula NS, Pendergrass SA, Actkins K, Davis LK, Velez Edwards DR, Holohan B, Ramirez A, Stanaway IB, Crosslin DR, Jarvik GP, Sleiman P, Hakonarson H, Williams MS, Michael Lee MT

doi: 10.1016/j.ajog.2020.04.004.

Reproductive Health

Loss of anti-Müllerian hormone (AMH) immunoactivity due to a homozygous AMH gene variant rs10417628 in a woman with classical polycystic ovary syndrome (PCOS)

Hum Reprod.

Hoyos LR, Visser JA, McLuskey A, Chazenbalk GD, Grogan TR, Dumesic DA

doi: 10.1093/humrep/deaa199.

Reproductive Health

Obstetric and neonatal outcome of ART in patients with polycystic ovary syndrome: IVM of oocytes versus controlled ovarian stimulation

Hum Reprod.

Mostinckx L, Segers I, Belva F, Buyl R, Santos-Ribeiro S, Blockeel C, Smitz J, Anckaert E, Tournaye H, De Vos M

doi: 10.1093/humrep/dez086.

Reproductive Health

Polycystic ovary syndrome (PCOS) and COVID-19: an overlooked female patient population at potentially higher risk during the COVID-19 pandemic

BMC Med.

Kyrou I, Karteris E, Robbins T, Chatha K, Drenos F, Randeva HS

doi: 10.1186/s12916-020-01697-5.

Pregnancy and Childbirth

Associations between polycystic ovary syndrome and adverse obstetric and neonatal outcomes: a population study of 9.1 million births

Hum Reprod.

Mills G, Badeghiesh A, Suarthana E, Baghlaf H, Dahan MH

doi: 10.1093/humrep/

Related content

Highly elevated level of antimüllerian hormone associated with preterm delivery in polycystic ovary syndrome patients who underwent ovulation induction

First-line ovulation induction for polycystic ovary syndrome: an individual participant data meta-analysis

The regulation and signalling of anti-Müllerian hormone in human granulosa cells: relevance to polycystic ovary syndrome

Significance of pro-angiogenic estrogen metabolites in normal follicular development and follicular growth arrest in polycystic ovary syndrome

A genome-wide association study of polycystic ovary syndrome identified from electronic health records

Loss of anti-Müllerian hormone (AMH) immunoactivity due to a homozygous AMH gene variant rs10417628 in a woman with classical polycystic ovary syndrome (PCOS)

Obstetric and neonatal outcome of ART in patients with polycystic ovary syndrome: IVM of oocytes versus controlled ovarian stimulation

Polycystic ovary syndrome (PCOS) and COVID-19: an overlooked female patient population at potentially higher risk during the COVID-19 pandemic

Associations between polycystic ovary syndrome and adverse obstetric and neonatal outcomes: a population study of 9.1 million births